Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001127855-14-000303
Filing Date
2014-07-01
Accepted
2014-07-01 15:11:06
Documents
10
Period of Report
2014-05-31

Document Format Files

Seq Description Document Type Size
1 NAPRODIS 10Q, 05.31.14 naprodis10q053114.htm 10-Q 296081
2 NAPRODIS 10Q, CERTIFICATION 302, CEO naprodisexh31_1.htm EX-31.1 9830
3 NAPRODIS 10Q, CERTIFICATION 302, CFO naprodisexh31_2.htm EX-31.2 9768
4 NAPRODIS 10Q, CERTIFICATION 906, CEO/CFO naprodisexh32.htm EX-32 6284
  Complete submission text file 0001127855-14-000303.txt   1373283

Data Files

Seq Description Document Type Size
5 napr-20140531_cal.xml EX-101.CAL 20570
6 napr-20140531_def.xml EX-101.DEF 7543
7 napr-20140531.xml EX-101.INS 155742
8 napr-20140531_lab.xml EX-101.LAB 68032
9 napr-20140531_pre.xml EX-101.PRE 54605
10 napr-20140531.xsd EX-101.SCH 10101
Mailing Address 13250 GREGG STREET SUITE F POWAY CA 92064
Business Address 13250 GREGG STREET SUITE F POWAY CA 92064 (858) 486-8655
Naprodis, Inc. (Filer) CIK: 0001313938 (see all company filings)

EIN.: 330903494 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 10-Q | Act: 34 | File No.: 333-122009 | Film No.: 14952115
SIC: 2834 Pharmaceutical Preparations